AstraZeneca Plans to Launch 100 New Medicines in China by 2029

AstraZeneca Plans to Launch 100 New Medicines in China by 2029

AstraZeneca is deepening its commitment to innovation in China, with plans to launch at least 100 new medicines within the next five years. Sharon Barr, the Executive Vice President of Biopharmaceuticals R&D at the global pharmaceutical giant, emphasized the importance of the company's R&D center in Shanghai during her recent interview with CGTN.

\"Our Shanghai R&D center plays a pivotal role in driving our innovation strategy,\" Barr stated. \"By collaborating closely with our Chinese partners, we aim to develop groundbreaking treatments that address the unique healthcare needs of the region.\"

This strategic move underscores AstraZeneca's dedication to fostering mutual interests and strengthening ties with Chinese collaborators. The company's focus on research and development in China not only accelerates the discovery of new medicines but also contributes to the local economy and healthcare advancements.

As the global pharmaceutical landscape evolves, AstraZeneca's investment in China positions it at the forefront of medical innovation, ensuring that cutting-edge therapies are accessible to patients both locally and worldwide.